Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that Dex-loaded hyaluronic acid hydrogel microneedles significantly reduced pain in an acute inflammatory visceral pain model without sedation, suggesting a promising and patient-friendly alternative to intravenous delivery.

Immunosuppressive therapy helps manage autoimmune diseases but carries risks like infection and potential for malignancy.

This study reported a 74% overall response rate for a new combination chemotherapy of mitoxantrone, etoposide, and prednisolone in patients with relapsed or refractory Hodgkin's disease or non-Hodgkin's lymphoma.

This study found that NIMP-R14-conjugated nanoparticles, loaded with roflumilast, effectively targeted neutrophils to reduce inflammation and improve symptoms in a mouse model of psoriasiform dermatitis, suggesting potential for targeted therapy in autoimmune skin diseases.

This document provides a legal disclaimer and offers no research findings.

This study found that mycophenolate mofetil is effective for both induction and maintenance therapy in children with severe lupus nephritis, significantly improving proteinuria and antibody levels, without renal flares during maintenance.

This study found that methylprednisolone can block IgG-induced keratinocyte detachment in an animal model of pemphigus vulgaris, potentially by increasing the synthesis and modifying adhesion molecules.

In this study, MMF plus prednisolone was found to induce remission in 81% of patients with proliferative lupus nephritis, with fewer adverse effects such as alopecia and amenorrhea compared to CYC plus prednisolone, despite similar overall remission rates.

This study found that the solid self-nanoemulsifying drug delivery system improved the oral bioavailability of carvedilol significantly compared to the drug alone, enhancing its solubility, dissolution, AUC, and Cmax.

This review discusses the mechanisms, uses, and side effects of conventional synthetic DMARDs, particularly methotrexate, for rheumatoid arthritis, but reports no new clinical findings.

This study found that both Elental and 6-mercaptopurine were effective for maintaining remission in Crohn's disease, without a significant difference between them over 24 months.

This study found that nanobubble-encapsulated diclofenac with ultrasound-targeted microbubble destruction (DNBs-UTMD) can enhance the anti-tumor efficacy of Doxil® by regulating the tumor immune microenvironment, improving drug uptake, and increasing T cell responses while reducing immune-suppressive cells in the process.

In this study, low concentrations of DMSO were found to decrease androgen receptor expression and inhibit the migration of prostate cancer cells, suggesting potential as an anticancer therapy.

Radiation therapy with a higher dose for the brain improves survival in cerebellar medulloblastoma.

In this study, the safety profiles of four treatments for early rheumatoid arthritis were assessed over one year, and the most serious side effects necessitating treatment discontinuation were noted in the leflunomide group, whereas no such withdrawals occurred in the methotrexate plus prednisolone group.

Mannitol diuresis allows higher doses of cis-platinum for testicular cancer treatment without increasing kidney damage.

This study found that patients with systemic lupus erythematosus reported improvements in symptoms such as fatigue and joint pain after Anifrolumab treatment, with a corresponding decrease in corticosteroid use, although some disease impacts on daily life remained.

This study reported that high-dose mizoribin therapy may be effective and safe for managing steroid-dependent pediatric systemic lupus erythematosus but requires monitoring of serum uric acid levels due to potential side effects.

This case report describes how anifrolumab, used beyond trial-eligible populations, led to significant clinical and serological recovery in a 45-year-old woman with organ-threatening systemic lupus erythematosus complicated by infection and resistant to conventional treatments like cyclophosphamide and rituximab.

In this study, oral mini-pulse methylprednisolone therapy for alopecia areata was reported to be effective and safe over 6 months, with 82.2% of patients recovering well and no adverse events observed.

This study observed that while all DMARD regimens had similar safety profiles, the leflunomide group experienced the most serious side effects leading to therapy discontinuation.

This review concludes that methotrexate remains an effective and safe first-line treatment for various inflammatory and immune-mediated skin conditions in children, despite the rise of biologic therapies.

In this case study, a 36-year-old female with severe lupus enteritis and intestinal pseudo-obstruction showed significant clinical improvement after treatment with intravenous methylprednisolone, hydroxychloroquine, and cyclophosphamide, highlighting the complexities and challenges in diagnosing and managing atypical lupus manifestations.

This study, involving patients with early rheumatoid arthritis, found that treatment regimens combining methotrexate and glucocorticoids, with or without initial high-dose methylprednisolone, showed higher remission rates over one year compared to methotrexate or leflunomide alone, and all regimens were generally well-tolerated.

In this study, the researchers reported that the safety profile was similar across all DMARD treatment regimens for early rheumatoid arthritis, but the most severe side effects occurred in the leflunomide group.

This study reported that Sintilimab combined with chemotherapy may improve outcomes in advanced NSCLC patients but carries a higher risk of certain side effects, including hypothyroidism.

This case report highlights a 31-year-old male with Adult Onset Still Disease, whose symptoms, including high fever, responded only to pulse-therapy with Methylprednisolone after failing to improve with usual treatments.

This case report describes a patient with SLE who developed acute inflammatory demyelinating polyneuropathy, experiencing significant improvement after treatment with intravenous immunoglobulin, methylprednisolone, and cyclophosphamide.

This study concluded that a sequential regimen of prednisolone and cyclophosphamide, followed by low-dose prednisolone and azathioprine, achieved favorable results in most patients with diffuse proliferative and/or membranous lupus nephritis without significant toxicities.

This study found that treating a murine model of systemic lupus erythematosus with early and optimally dosed mesenchymal stem cells effectively suppressed disease severity.